Please assess the completion status of the following clinical trial:

Trial Title: Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mantle cell lymphoma (MCL), meeting the following criteria:~  * Diagnosis confirmed by examination of representative material (lymph nodes or bone marrow) together with a typical immunophenotype CD5+, CD23-, sIgM, cyclin D1 nuclear positivity is desirable but not essential~ * Central review of histology will be performed on diagnostic material~ * Molecular or cytogenetic confirmation of diagnosis is not required~* Previously untreated disease at any stage requiring therapy in the opinion of the treating physician~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 3 months~  * Life expectancy not severely limited by other illness~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during study therapy~* No known serological positivity for HBV, HCV, or HIV~* No concurrent uncontrolled serious medical conditions~* No severe impairment of renal or liver function (alkaline phosphatase, bilirubin or creatinine \> 2.5 times upper limit of normal) not related to lymphoma~* No known hypersensitivity to murine proteins~* No prior malignancy in the past 5 years, except for nonmelanoma skin tumor or curatively resected carcinoma in situ of the uterine cervix~* No history of a psychological illness or condition that, in the opinion of the investigator, may adversely affect compliance with study medication~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine/Cyclophosphamide/Rituximab (Type: EXPERIMENTAL): Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion~Every 28 days
- Fludarabine/Cyclophosphamide (Type: ACTIVE_COMPARATOR): Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3~Every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).